ARIAD Pharma (ARIA) Misses Q3 EPS by 6c

ARIAD Pharma (NASDAQ: ARIA) reported Q3 EPS of ($0.29), $0.06 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $27.5 million versus the consensus estimate of $46.09 million.

Shipments of Iclusig to patients in France were $2.2 million for the third quarter of 2015. Cumulative total shipments in France totaled $23.3 million through September 30, 2015. We will record revenue related to cumulative shipments in France upon completion of pricing and reimbursement negotiations in France, net of any amounts that will be refunded to the French health authorities as a result of these negotiations, which we anticipate will be completed by year-end 2015.

Advancing the Pipeline

• We are on track to file an investigational new drug (IND) application for AP32788 by year-end 2015 and to begin a Phase 1/2 proof-of-concept clinical trial in 2016. AP32788 is an orally active tyrosine-kinase inhibitor (TKI), which has a unique profile against a validated class of mutated targets in NSCLC and certain other solid tumors and may address an important unmet medical need.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c